AMGN vs RVMD stock comparison
Amgen vs. Revolution Medicines · data as of November 13, 2026
Amgen (AMGN) has a market value of about $251.9B, Revolution Medicines (RVMD) about $37.3B. Over their latest twelve months Amgen had revenue of $38.9B and Revolution Medicines $198M.
On our five checks Amgen scores higher: 2.4 out of 5 (weak) against 0.6 (weak).
By area, the stronger company is Amgen on future growth; Amgen on track record; Amgen on shareholder returns.
Amgen leads on 12 of the compared lines and Revolution Medicines on 1.
Side by side
| AMGN | RVMD | |
|---|---|---|
| Size and price | ||
| Market cap | $251.9B | $37.3B |
| Share price | $465.67 | $172.29 |
| Score | ||
| Overall score (of 5) | 2.4 | 0.6 |
| Value | 0 | 0 |
| Future growth | 3 | 1 |
| Track record | 3 | 0 |
| Financial health | 2 | 2 |
| Shareholder returns | 4 | 0 |
| Valuation | ||
| P/E (TTM) | 27.0 | — |
| Forward P/E | 19.5 | — |
| Price / free cash flow | 26.3 | — |
| Price / sales | 6.5 | 188.6 |
| EV / EBITDA | 17.1 | — |
| PEG | 9.18 | — |
| DCF value vs. price | −26% | — |
| Business | ||
| Revenue | $38.9B | $198M |
| Net income | $9.4B | -$1.9B |
| Free cash flow | $9.6B | -$1.4B |
| Net margin | 24.1% | -946.8% |
| Gross margin (5-yr avg.) | 69.9% | — |
| ROIC (5-yr avg.) | 13.5% | -36.5% |
| Growth | ||
| Revenue growth (1 yr) | 10.0% | — |
| Revenue growth (5 yrs, per year) | 7.6% | -100.0% |
| EPS growth (5 yrs, per year) | 2.9% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$40.8B | — |
| Dividend yield | 2.16% | None |
| Shareholder yield | 2.2% | 0.0% |
| Analysts | ||
| Upside to average target | −7% | +59% |
| Consensus rating | Hold | Strong buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: AMGN TTM to September 30, 2026, RVMD TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Amgen or Revolution Medicines?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Amgen scores 2.4 out of 5 and Revolution Medicines 0.6; the table shows where each one is stronger.
Which grows faster, Amgen or Revolution Medicines?
Over five years Amgen grew revenue about 7.6% a year and Revolution Medicines about -100.0% a year.
Which pays a higher dividend?
Amgen yields 2.16% and Revolution Medicines nothing (no dividend).
Full Amgen analysis → Full Revolution Medicines analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.